Medibiofarma has just closed a financing round of 1.2 million euros, supported by the founder’s and other VC partners with proven experience in the field of health and technology, such as Sodena (Public company of the Government of Navarra), Inveready and Fitalent (Everis).

Associated with this private equity financing, the company obtained an ENISA loan of 500,000 euros and a subsidy through the CDTI Misiones aid program of 570,000 euros.

This new financing will cover the needs of the company in the next two years, including the clinical development of its three research programs, generating value in each of them and reaching clinical milestones that will open the possibility of signing licensing agreements with Big pharmaceuticals companies, one of the main objectives of the company in the next two years.

Medibiofarma, since its foundation in 2016, has managed to discover, patent and bring to clinical trials three novel drugs to treat diseases of high medical need such as cancer and neurodegenerative diseases. The support of its partners has been key to meeting these milestones, which has made it possible to create a team endowed with experience and know-how that is clearly differential and extraordinary between the companies in the sector.

“Our company has one of the most innovative product pipelines in the European biotech landscape, and this additional funding will help us generate new clinical data in each of the projects. Our thanks once again to the trust placed by our partners, especially by Sodena, the company’s main investor since its creation,” stated Rodolfo Rodríguez, CEO and founder of Medibiofarma.